Lugano, Switzerland, 2 December 2024 – The ESMO Immuno-Oncology Congress 2024 will take place in Geneva, Switzerland, from December 11-13, with an option to attend virtually. Leading experts will present and discuss the research advancements in the rapidly evolving field of immuno-oncology. Topics will include new therapeutic opportunities, interpretation of recent data and management of treatment-related toxicities.
Programme highlights
- Results from a phase 3 trial on gut microbiota as a potential biomarker for chemo-immunotherapy in non-small cell lung cancer and novel data on the role of gut microbiota in immunotherapy efficacy and toxicity.
- New insights on the efficacy of early immunotherapy in patients with unresectable non-small cell lung cancer or who refused surgery.
- Related content: Abstract 117O
- Novel findings on the potential of liquid biopsy and circulating tumor DNA in immunotherapy: new insights into the biological characteristics of individual patients.
- Related content: Abstracts 4MO, 6MO
- Data on potential treatment approaches that integrate immunotherapy and (chemo)radiotherapy to improve outcomes for patients with non-small cell lung cancer.
- Insights on scientific advances in immuno-oncology in 2024, with a focus on immuno-biology and clinical applications.
- Relate content: Special Session on Wednesday 11 December, 14:15-15:45; Special Session on Friday 13 December, 13:00-14:30 CET
Keynote Lectures
- Award keynote address “Dissecting T cell recognition of human cancer” by Ton N. Schumacher, 11 December 2024, 13:40-14:05 CET
- Keynote address “Neoadjuvant CPI” by Christian U. Blank, 12 December 2024, 13:35-14:00 CET
The results of the studies presented at the congress will be published online as a supplement to IOTECH. The abstract titles and sessions can be viewed in the online programme.
Press accreditation
ESMO welcomes press representatives working for recognised press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities and the embargo schedule for ESMO Immuno-Oncology Congress 2024. To apply for press accreditation, please fill out the form available here. Please be kindly informed that onsite press accreditations will not be available.
Third Parties Media registration
Third Parties Media representatives and Filming Crews not eligible as press, must abide by the ESMO Policy on Media Activities Organised by Third Parties and can request a Third Parties Media badge through registration@esmo.org (Cc media@esmo.org).
Further information
ESMO Press Office
press@esmo.org
Notes to Editors
Please make sure to use the official name of the meeting in your reports: ESMO Immuno-Oncology Congress 2024 and the official congress hashtag #ESMOImmuno24. Follow it to stay up to date and use it to take part in the conversation on X(Twitter), LinkedIn, Facebook, Instagram, YouTube.
About the European Society for Medical Oncology (ESMO)
Representing more than 40,000 oncology professionals from more than 170 countries and territories worldwide, ESMO is a reference for oncology education and information. Driven by a shared determination to secure the best possible outcomes for patients, ESMO is committed to standing by those who care about cancer through addressing the diverse needs of #ONEoncologycommunity, offering #educationforLIFE, and advocating for #accessiblecancerCARE. www.esmo.org